| Market Cap | 24.5B |
| Market Cap (USD) | $3.4B |
| P/E Ratio | - |
| P/B Ratio | - |
| EPS | 0.63 |
| Dividend Yield | - |
| D/E Ratio | 0.33 |
| Current Ratio | 2.13 |
| Market Segment | ChiNext |
| Currency | CNY |
Business Overview
Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. The company offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; ursodeoxycholic acid; coenzyme Q10 mycelia; and other products. It also provides synthetic biology products, including bisabolol, 5-hydroxytryptophan, ergothioneine, ekdoin, inositol, squalane, polyhydroxyalkanoate (PHA), and phytosphingosine. In addition, the company engages in trading, crop planting, inspection, technical advisory, and asset investment activities. The company was incorporated in 2010 and is based in Yining, China. Yili Chuanning Biotechnology Co.,Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
Key Financial Metrics
Profitability
Returns & Efficiency
Financial Health
| Industry | C27医药制造业 |
| Market Segment | ChiNext |
| Currency | CNY |
| Fiscal Year | 2024 |
Stock Chart
Full charting with technical indicators, candlestick, line charts, and more.
Company Profile
| Company Name | 川宁生物 |
| Ticker | 301301 |
| Exchange | SZSE |
| Sector | 证监会行业分类 |
| Industry | C27医药制造业 |
| Market Segment | ChiNext |
| Fiscal Year | 2024 |
| Currency | CNY |
| Market Cap | 24.5B |
| Market Cap (USD) | $3.4B |
| Revenue | 5.8B |
| Net Income | 1.4B |
| P/E Ratio | - |
| EPS | 0.63 |
| Net Margin | 24.3% |
| ROE | 17.7% |
| Dividend Yield | - |
Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. The company offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; ursodeoxycholic acid; coenzyme Q10 mycelia; and other products. It also provides synthetic biology products, including bisabolol, 5-hydroxytryptophan, ergothioneine, ekdoin, inositol, squalane, polyhydroxyalkanoate (PHA), and phytosphingosine. In addition, the company engages in trading, crop planting, inspection, technical advisory, and asset investment activities. The company was incorporated in 2010 and is based in Yining, China. Yili Chuanning Biotechnology Co.,Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.